New Mid-term Business Plan
“IBI 21”

Tatsuro Kosaka
President and CEO
CHUGAI PHARMACEUTICAL CO., LTD.

January 31/ February 1, 2019

Forward-Looking Statements

This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual results may differ from expectations based on risks and uncertainties that may affect the Company’s businesses.

Note: Amounts shown in this report are rounded to the nearest 0.1 billion yen.
Variance and % are calculated based on the amounts shown.

Review of 2016 – 2018
Mid-term Business Plan “IBI 18”

Business Performance during IBI 18



2015-18 CAGR*

Revenue +5.1%

Core OP +12.8%

Core EPS +14.9%

Core EPS	116.4 JPY	102.5 JPY	138.7 JPY	176.4 JPY

IBI 18 Target	Initial Target	Result	Status
Core EPS CAGR* (2015-18)	Low single digit**	17.1%**	✓

*CAGR: Compound Annual Growth Rate (%) ** 3 years, average constant exchange rate for 2015

Summary of IBI 18

Achieving record high profit, Chugai is enriching our platforms for further growth

		Status
Financial targets	● Posted consecutive record revenues and operating profit ● Achieved industry-leading market capitalization	✓
Priority agenda: Acquisition and implementation of global top-class competitiveness	● Continuously generated new antibody projects and enhanced drug discovery platform for middle molecules ● Obtained early approval for Hemlibra ● Obtained Tecentriq approval and simultaneously developed drugs for 19 indications ● Established system to manage FDA GMP inspections ● Established framework to execute regional strategy through collaboration of 3 Chugai divisions (Marketing & Sales/Medical Affairs/Safety) ● Made steady inroads towards accelerated growth based on Hemlibra and Tecentriq	✓
Priority agenda: Selection and concentration for accelerated growth		

Realization of Becoming a Top Pharmaceutical Company

Goals of “Top Pharmaceutical Company”

Corporate Vision	**Company that focuses on first-in-class/best-in-class products and services, and continuously provides new solutions to patients and medical communities around the world —Innovation all for patients—**

Quantitative Targets (in late 2010s)

- ✓ Gain a position among the top 3 major Japanese pharmaceutical companies
- ✓ No. 1 presence in our strategic therapeutic areas in Japan
- ✓ Expanded presence in global market

Qualitative Targets (in late 2010s)

- ✓ A company that satisfies all its stakeholders and receives their active support and trust
- ✓ A company that works proactively on a global level

Top Pharma: Quantitative Targets (1)

Goal: Rank within the top 3 major Japanese pharmaceutical companies in the following categories

Domestic sales share	5th*
Consolidated operating profit margin ✓	2nd
Consolidated operating profit per employee ✓	2nd
Domestic sales per MR ✓	1st**

Goal: No.1 domestic presence in strategic disease areas

	Market share	Stakeholder satisfaction
Oncology ✓	1st*	1st***

Renal: 2nd*/2nd***, Bone & Joint: 2nd*/2nd***, RA (biologics): 2nd*/1st***

Goal: No.1 presence in hospital market based on medical care networks linking healthcare providers

	Market share	Stakeholder satisfaction
Share of hospital sales (≥100 beds) ✓	1st*	1st***

Top Pharma: Quantitative Targets (2)

Goal: Expansion of global presence

Increase overseas sales ratio	2008: 10.4% 2018: 24.2%
Possess 3 major global products	Actemra Alecensa Hemlibra
Number of global projects in late-stage development (possess ≥3 projects)	nemolizumab satralizumab SKY59 (expected)
Continuous addition of FIC/BIC in-house projects to the portfolio (average 3 projects /year)	During IBI 18 8 projects/ 3 years

Top Pharma: Qualitative Targets (1)

Goal: A company that satisfies all its stakeholders and receives their active support and trust

【Patients and Healthcare Professionals】

Play a part in increasing treatment satisfaction and the contribution of drugs in cancer treatments in our capacity as a leading oncology company ✓

【Shareholders and Investors】

Realize growth strategies based on innovation
(market capitalization: 31st in Japan overall, 1st in domestic pharmaceutical industry) ✓

※as of Dec. 28, 2018

【Roche】

Contribute to growth of Roche Group by out-licensing Actemra, Alecensa, and Hemlibra.
Realize revenue and profit growth by fully leveraging our alliance with Roche. ✓

Top Pharma: Qualitative Targets (2)

Goal: A company that works proactively on a global level

Continuous creation, development, and domestic and overseas launches of products with a competitive advantage in clinical results ✓

- FDA breakthrough therapy designation for 7 times in 4 products (No. 1 in domestic pharm.)
- Establish world-class manufacturing base (completion of HEM/ALC global inspections)

Contribution to the Roche Group's results through product-appropriate fostering and sales ✓

- Maximize product value through simultaneous global development and filing of Roche products
- No. 1 customer satisfaction in strategic disease areas by establishing a system for providing new solutions

Leadership in pharmaceutical industry activities ✓

- Promote personalized healthcare in Japan
- Become an industry leader in biotechnology
- Lead the field of drug safety by establishing a system to provide value-added safety information

Activities in which all employees have an awareness, sense of responsibility and pride as part of a top pharmaceutical company ✓

- Raise awareness among employees of Chugai's goal of becoming a top pharmaceutical company
- Become a world-class company in employees engagement
- Facilitate human resource development that also creates win-win relationships at the individual level through collaboration with Roche

Realization of Top Pharmaceutical Company

CHUGAI
Roche Roche Group

Mid-Term Business Plan IBI 18

- Acquisition and implementation of global top-class competitiveness
- Selection and concentration for accelerated growth

Status

- R&D targets
- Share and presence targets
- Financial targets

✓

Top Pharmaceutical Company

- A company that works proactively on a global level
- A company that satisfies all its stakeholders and receives their active support and trust

Major quantitative targets

✓

Envisioned Future

As a most important member of the Roche group, we aim to become a top Japanese pharmaceutical company by providing a continuous flow of innovative new medicines domestically and internationally.

✓

Business Environment and Vision for Growth

Drastic Reforms Required for Healthcare Industry while Experiencing Big Changes in the Environment

CHUGAI
Roche Roche Group

Mega-trends

Exponential changes



Simultaneous global threats

Remarkable advances in life sciences and digital technologies

Dramatic demographic shifts

Threats to sustainability of global environment and social systems

Impact on healthcare industry

Higher benchmarks set for innovation

- **Falling drug prices due to clampdown on healthcare costs**
- **Stricter evaluation of cost-effectiveness**

Increased calls to participate in resolving social issues

Chugai’s Basic Policy

Striving for the mutual development of Chugai and Society by solving social issues through the creation of innovative drugs and services

Chugai growth and development = **Creation of value shared by Chugai and Society**
Realize advanced and sustainable patient-centric healthcare = Social growth and development

Increased corporate value

Resolution of social issues

Focus on innovation

Creation of innovative drugs and services

- **Strategic alliance with Roche**
- **Our science and technologies**

Chugai business model adopted

Key issues selected by Chugai (materiality)

- Sustainable Healthcare
- Human Rights
- Supply chain management
- Human Resources
- Social Contribution
- Global Environment
- Governance
- Ethics and Compliance

Renewal of Core Values & Envisioned Future

CHUGAI

Roche Roche Group

Mission Statement
~Innovation all for the patients~

No change:
Maintain as starting point

Mission

Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world

Change:
Succinctly describe the most important value assessment criteria

Core Values

1. Patient Centric	Make each patient’s wellbeing our highest priority
2. Pioneering Spirit	Pursue innovation by improving ourselves and thinking differently
3. Integrity	Maintain the highest standards in all we do to create shared value with society

Change:
Redefine the aspect of evolving with society as a higher objective

Envisioned Future

Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strength in science and technology and the alliance with Roche

FY2019-21 New Mid-term Business Plan “IBI 21”

Name of New Mid-Term Business Plan

While maintaining the concept of “IBI” which express our attitude to pursue continuous innovation and creation, “21” expresses the new stage in which we will take on new challenges.

IBI 21

IBI: INNOVATION BEYOND IMAGINATION

New Mid-Term Business Plan: 5 Strategies

Accelerate corporate and social development through innovation focused on innovative products

Create global growth drivers and maximize value

1 Value Creation

Realize innovative drug discovery
to cure and manage diseases

2 Value Delivery

Deliver patient-centric solution
to maximize value of growth drivers

3 Promote advances in personalized healthcare

Realize the further advancement of PHC and innovate R&D process
by utilizing digital technology and data

Strengthen HR and infrastructure that support Chugai’s business

4 Human capital and structural reform

Develop high-caliber HR talent that support innovation,
and drastically reform costs, systems and processes

5 Strengthen sustainable platforms

Simultaneously realize company growth and sustainable social development

Strategy 1: Value Creation

Realize innovative drug discovery to cure and manage diseases by integrating our core drug discovery techniques and biology, and by achieving rapid PoC



Strategy 2: Value Delivery

Maximize growth drivers (innovative drugs and services) through patient centric consulting and digital solution

Maximize value of growth drivers

Promote FMI business in Japan

Provide solutions through integration between collaboration in variety of specialists and digital technology

- Deepen 3 Divisions' collaboration and deliver sophisticated consulting
- Advancement of treatment support/ solution utilizing digital technology

Additional value to realize personalization and differentiation

- High quality evidence including RWE
- Real-time safety information

Innovative drugs/services such as Hemlibra/Tecentriq

Strategy 3: Promote Advances in PHC

Realize further advancements in PHC and innovate R&D process through ‘PHC2.0’ by utilizing digital technology and data

Further advance PHC and innovate R&D process

Collaboration with Roche

- Utilize Roche Assets (e.g. Flatiron)

Promote PHC 2.0 to create value

- Advance in cancer genome diagnostics (FMI) (e.g. accelerate developing liquid biopsy etc.)
- Develop high-quality medical DB in collaboration with medical institutes
- ✕
- Generate insights by establishing data utilization structure and advanced data analysis

Intelligence

- Collect information incl. science and digital technology
- Confirm feasibility of digital devices

Strategy 4: Strengthen Human Capital and Conduct Drastic Structural Reform

Recruit and develop diverse and high-caliber HR talent that support innovation, and conduct drastic structural reforms

Accelerate innovation by implementing strategies ①–③

Strengthen business platforms

Recruit and develop HR talent

- Strengthen talent management system
- Diversity & Inclusion
- Reform remuneration system

Drastic structural reform

- Structural reform by reviewing costs, systems and processes
- ✖
- Shift resources to facilitate innovation

Strategy 5: Strengthen Sustainable Platforms

With the aim of improving corporate value continuously, specify 6 priority agendas that support our challenge toward innovation, based on expectation/request from the society, economic/environmental/social effects by Chugai, and interest of stakeholders.

Corporate value = **Economic value** + **Social value**

IBI 21 Quantitative Outlook

Under the new mid-term business plan, we will make essential investment for future growth, while maintaining the momentum of growth achieved during IBI 18, and realize sustainable profit growth and expansion of corporate value.

Core EPS CAGR* (2018 – 2021)	**High single digit****

* Compound Annual Growth Rate (%)

** 3 years, based on constant exchange rate

Basic Policy of Shareholder Returns

Profit	To be distributed considering the balance between internal reserves necessary for increasing corporate value, and profit distribution with shareholders
Dividend Policy	Aim for a dividend payout ratio of 50% on average in comparison with Core EPS to provide a stable dividend to shareholders
FY2019 Dividend	96 JPY (forecast)

IBI 21 Growth Outlook

In addition to market penetration of growth drivers in Japan and overseas, the approval and launch of satralizumab will support further growth



FY2018 Consolidated Financial Overview (IFRS based)

Toshiaki Itagaki
Executive Vice President and CFO
CHUGAI PHARMACEUTICAL CO., LTD.

January 31/ February 1, 2019

Full Year Results Summary

■ **Revenues: 579.8 billion yen (+45.6, +8.5% YoY)**

- Domestic sales excl. Tamiflu: despite impact from HIP revision, slight increase due to steady sales growth of mainstay products (+0.8, +0.2%)
- Overseas sales: increase in exports of Actemra and Alecensa to Roche (+33.9, +36.1%)
- Royalties and other operating income: one-time income from transfer of long-term listed products, and from out-licensing of developed products, etc. (+17.0, +48.7%)

■ **Cost of sales / Operating expenses (Core basis)**

- Cost of sales: the ratio to sales improved due to a change in product mix, etc. (-1.1% points, from 50.7% to 49.6%)
- Operating expenses: overall increase mainly due to increase of research and development expenses and general administration expenses, etc. (-9.5, +5.3%)

■ **Profits**

- IFRS results: operating profit 124.3 billion yen (+25.4, +25.7%)
  net income 93.1 billion yen (+19.6, +26.7%)
- Core results: operating profit 130.3 billion yen (+27.1, +26.3%)
  net income 97.3 billion yen (+20.6, +26.9%)
- Core EPS (JPY): 176.42 (+37.74, +27.2%)

IFRS and Core Results Jan-Dec

(Billion JPY)	IFRS results 2018 Jan. - Dec.	Non-core items		Core results 2018 Jan. - Dec.
		Intangible assets	Others	
Revenues	**579.8**			**579.8**
Sales	527.8			527.8
Royalties and other operating income	51.9			51.9
Cost of sales	-262.8	+1.0		-261.9
Gross profit	**316.9**	**+1.0**		**317.9**
Operating expenses	**-192.6**	**+5.0**		**-187.6**
Marketing and distribution	-73.7			-73.7
Research and development	-99.2	+5.0		-94.2
General and administration	-19.7			-19.7
Operating profit	**124.3**	**+6.0**		**130.3**
Financing costs	-0.1			-0.1
Other financial income (expense)	0.4			0.4
Other expense	-3.2			-3.2
Profit before taxes	**121.4**	**+6.0**		**127.5**
Income taxes	-28.4	-1.8		-30.2
Net income	**93.1**	**+4.2**		**97.3**
Chugai shareholders	92.5	+4.2		96.7
Non-controlling interests	0.6			0.6

(Billions of JPY)

Non-Core items

Intangible assets:
- Amortization of intangible assets +1.2
- Impairment +4.8

Others
- none

Core net income attributable to Chugai shareholders 96.7

(Millions of shares)

Weighted average number of shares in issue used to calculate diluted earnings per share 548

(JPY)

Core EPS 176.42

Year on Year (Core)

Financial Overview Jan-Dec

(Billions of JPY)	2017 Jan - Dec vs. Revenues		2018 Jan - Dec vs. Revenues		Growth	
Revenues	**534.2**		**579.8**		**+45.6**	**+8.5%**
Sales	499.3		527.8		+28.5	+5.7%
excl. Tamiflu	482.4		517.2		+34.8	+7.2%
Domestic	388.4		389.2		+0.8	+0.2%
Export to Roche	76.4		109.9		+33.5	+43.8%
Other overseas	17.7		18.0		+0.3	+1.7%
Tamiflu	16.9		10.7		-6.2	-36.7%
Ordinary	11.9		10.1		-1.8	-15.1%
Govt. stockpiles, etc.	5.0		0.5		-4.5	-90.0%
Royalties and other operating income	34.9		51.9		+17.0	+48.7%
Cost of sales	-252.9	47.3%	-261.9	45.2%	-9.0	+3.6%
Gross profit	**281.3**	**52.7%**	**317.9**	**54.8%**	**+36.6**	**+13.0%**
Operating expenses	-178.1	33.3%	-187.6	32.4%	-9.5	+5.3%
Operating profit	**103.2**	**19.3%**	**130.3**	**22.5%**	**+27.1**	**+26.3%**
Financing costs	-0.1		-0.1		0.0	0.0%
Other financial income (expense)	-0.1		0.4		+0.5	-
Other Expenses	-1.7		-3.2		-1.5	+88.2%
Income taxes	-24.5		-30.2		-5.7	+23.3%
Net income	**76.7**	**14.4%**	**97.3**	**16.8%**	**+20.6**	**+26.9%**
EPS (JPY)	138.68		176.42		+37.74	+27.2%

Royalties and other operating income +17.0

One-time income from transfer of long-term listed products, and from out-licensing developed products, etc.

Other financial income (expense) +0.5

Exchange gains/losses +0.5

Gains/Losses on derivatives (Gains/Losses on foreign exchange forward contracts) +0.0

Other Expenses -1.5

Settlement for transfer pricing taxation

Cost of sales ratio vs. Sales

2017 Jan – Dec	2018 Jan – Dec
50.7%	49.6%

Market average exchange rate (JPY)

	2017 Jan – Dec	2018 Jan - Dec
1 CHF	113.90	112.92
1 EUR	126.39	130.36
1 USD	112.17	110.45
1 SGD	81.22	81.87

Year on Year

Sales (excl. Tamiflu) Jan-Dec

Sales by Disease Area, Year on Year Comparisons

(Billions of JPY)



Sales by Products, Year on Year Changes



*) Details of HER2 franchise

Herceptin (28.1)	-5.5,	-16.4%
Perjeta (16.1)	+2.5,	+18.4%
Kadcyla (8.5)	+0.5,	+6.3%

( ): Actual sales in FY2018
%: Year-on-year percentage change

Tamiflu Sales Trends

(Billions of JPY)	Fiscal Term Sales											
	FY2013		FY2014		FY2015		FY2016		FY2017		FY2018	
	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec	Jan-Jun	Jul-Dec
Ordinary	8.2											
		1.9	7.0									
				5.8	6.7							
						1.5	7.3					
								4.7	6.3			
										5.6	8.3	
												1.8
	10.1	**(-0.1)**	**12.9**	**(+2.8)**	**8.2**	**(-4.7)**	**12.0**	**(+3.8)**	**11.9**	**(-0.1)**	**10.1**	**(-1.8)**
Govt. Stockpiles etc.	0.8	0.1	0.1	0.1	0.0	0.0	0.0	1.5	1.9	3.1	0.1	0.4
	0.9	**(-1.0)**	**0.2**	**(-0.7)**	**0.0**	**(-0.2)**	**1.5**	**(+1.5)**	**5.0**	**(+3.5)**	**0.5**	**(-4.5)**
Total	**9.0**	**2.0**	**7.1**	**5.9**	**6.7**	**1.5**	**7.3**	**6.2**	**8.2**	**8.7**	**8.4**	**2.2**
	11.0	**(-1.0)**	**13.0**	**(+2.0)**	**8.2**	**(-4.8)**	**13.5**	**(+5.3)**	**16.9**	**(+3.4)**	**10.7**	**(-6.2)**

( ) Year on year

Season (from the second half of FY to the first half of the next FY)	
2012	**10.6**
2013	**9.0**
2014	**12.6**
2015	**8.7**
2016	**11.0**
2017	**14.0**

Year on Year (Core)

Operating Profit Jan - Dec

(Billion of JPY)



(Billions of JPY)	2017 Jan - Dec	2018 Jan - Dec	Growth
Revenues	**534.2**	**579.8**	**+45.6**
Cost of sales	-252.9	-261.9	-9.0
Gross profit	**281.3**	**317.9**	**+36.6**
Sales	246.4	266.0	+19.6
Royalties, etc.	34.9	51.9	+17.0
Marketing and distribution	-72.8	-73.7	-0.9
Research and development	-88.9	-94.2	-5.3
General and administration	-16.3	-19.7	-3.4
Operating profit	**103.2**	**130.3**	**+27.1**

Increase in gross profit from sales +19.6
Increase in export to Roche and improvement of cost of sales ratio to sales due to change in product mix, etc.

Increase in royalties and other operating income +17.0

Increase in marketing and distribution expenses -0.9

Increase in research and development expenses -5.3
Progress of projects, etc.

Increase in general and administration expenses, etc. -3.4
Increase in various expenses, including legal expenses and the enterprise tax, etc.

Year on Year (Core)

Financial Overview Oct - Dec

(Billions of JPY)	2017 Oct - Dec	vs. Revenues	2018 Oct - Dec	vs. Revenues	Growth	
Revenues	**146.6**		**153.3**		**+6.7**	**+4.6%**
Sales	134.5		139.1		+4.6	+3.4%
excl. Tamiflu	127.7		137.3		+9.6	+7.5%
Domestic	107.5		107.3		-0.2	-0.2%
Export to Roche	15.8		25.8		+10.0	+63.3%
Other overseas	4.5		4.3		-0.2	-4.4%
Tamiflu	6.8		1.8		-5.0	-73.5%
Ordinary	5.6		1.8		-3.8	-67.9%
Govt. stockpiles, etc.	1.2		-		-1.2	△100.0%
Royalties and other operating income	12.0		14.2		+2.2	+18.3%
Cost of sales	-67.3	45.9%	-67.6	44.1%	-0.3	+0.4%
Gross profit	**79.2**	**54.0%**	**85.8**	**56.0%**	**+6.6**	**+8.3%**
Operating expenses	-54.7	37.3%	-58.7	38.3%	-4.0	+7.3%
Operating profit	**24.5**	**16.7%**	**27.1**	**17.7%**	**+2.6**	**+10.6%**
Financing costs	-0.0		-0.0		0.0	0.0%
Other financial income (expense)	0.1		0.5		+0.4	+400.0%
Other Expenses	-0.6		-1.1		-0.5	+83.3%
Income taxes	-6.9		-3.8		+3.1	-44.9%
Net income	**17.1**	**11.7%**	**22.7**	**14.8%**	**+5.6**	**+32.7%**
EPS (JPY)	30.88		41.28		+10.40	+33.7%

Increase in gross profit from sales +4.4

Increase in export to Roche and improvement of cost of sales ratio to sales

Increase in royalties and other operating income +2.2

Increase in milestone income

Increase in operating expenses -4.0

Decrease in marketing and distribution +0.3

Increase in research and development -2..1

Progress of projects, etc.

Increase in general and administration, etc. -2.2

Increase in legal expenses, etc.

Cost of sales ratio vs. Sales

2017 Oct – Dec	2018 Oct – Dec
50.0%	48.6%

Market average exchange rate (JPY)

	2017 Oct – Dec	2018 Oct - Dec
1 CHF	114.41	113.33
1 EUR	132.93	128.72
1 USD	112.89	112.84
1 SGD	83.38	82.04

vs. Forecast (Core)

Financial Overview Jan - Dec

(Billions of JPY)	2018 Jan - Dec Forecast	Actual	+/-	Achievement
Revenues	**541.5**	**579.8**	**+38.3**	**107.1%**
Sales	498.5	527.8	+29.3	105.9%
excl. Tamiflu	492.9	517.2	+24.3	104.9%
Domestic	374.8	389.2	+14.4	103.8%
Export to Roche	99.6	109.9	+10.3	110.3%
Other overseas	18.5	18.0	-0.5	97.3%
Tamiflu	5.6	10.7	+5.1	191.1%
Royalties and other operating income	43.0	51.9	+8.9	120.7%
Cost of sales	-252.0	-261.9	-9.9	103.9%
Gross profit	**289.5**	**317.9**	**+28.4**	**109.8%**
Operating expenses	-181.5	-187.6	-6.1	103.4%
Operating profit	**108.0**	**130.3**	**+22.3**	**120.6%**
EPS (JPY)	147.00	176.42	+29.42	120.0%

Increase in gross profit from sales +19.4

Increase in domestic sales and export to Roche, and improvement of cost of sales ratio to sales due to a change in product mix, etc.

Increase in royalties and other operating income +8.9

Increase in one-time income from out-licensing developed products, etc.

Increase in operating expenses -6.1

Increase in legal expenses and expenses for further market penetration of new products and mainstay products

Cost of sales ratio vs. Sales

2018 Jan – Dec Forecast	2018 Jan – Dec Actual
50.6%	49.6%

Exchange rate (JPY)

	2018 Jan – Dec Assumption	2018 Jan – Dec Actual *
1 CHF	115.00	112.92
1 EUR	133.00	130.36
1 USD	111.00	110.45
1 SGD	84.00	81.87

* Market average exchange rate for the period Jan – Dec.

vs. Forecast (Core)

Sales Progress (excl. Tamiflu) Jan - Dec

(Billions of JPY)

Sales by Disease Area, Actual vs. Forecast



Sales by Products, Actual vs. Forecast



*) Details of HER2 franchise

Herceptin (28.1)	+1.5,	+5.6%
Perjeta (16.1)	+1.5,	+10.3%
Kadcyla (8.5)	+0.2,	+2.4%

( ): FY2018 Actual
%: Achievement

vs. Forecast (Core)

Impact from Foreign Exchange

(Billions of JPY)	FX impact Jan – Dec 2018 (FX impact vs. Assumption)	
Revenues	**-1.2**	
	Sales	-0.7
	Royalties and other operating income	-0.5
Cost of sales Operating expenses	Cost of sales	+0.3
	Expenses	+0.6
Operating profit	**-0.3**	

Actual / Forecast rate* (JPY)	2017 Jan - Dec Actual	2018 Jan -Dec Assumption	2018 Jan - Dec Actual
1CHF	113.90	115.00	112.92
1EUR	126.39	133.00	130.36
1USD	112.17	111.00	110.45
1SGD	81.22	84.00	81.87

* Actual: market average exchange rate for the period Jan - Dec

[Reference]
Historical exchange rate to the JPY





vs. 2017 Year End

Overview of Financial Position

(Billions of JPY)	2017 Dec	2018 Dec	Change
Trade accounts receivable	148.5	150.8	+ 2.3
Inventories	169.1	159.4	- 9.7
Trade accounts payable	-38.4	-35.9	+ 2.5
Other net working capital	-28.4	-39.1	- 10.7
Net working capital *1	250.7	235.1	- 15.6
Property, plant and equipment	171.6	222.4	+ 50.8
Intangible assets	21.1	22.7	+ 1.6
Other long-term assets - net	-3.1	25.1	+ 28.2
Long-term net operating assets *2	189.5	270.1	+ 80.6
Net operating assets	440.2	505.3	+ 65.1
Debt	-0.3	-0.2	+ 0.1
Marketable securities	104.0	102.5	- 1.5
Cash and cash equivalents	139.1	146.9	+ 7.8
Net cash	242.8	249.2	+ 6.4
Other non-operating assets - net	9.9	2.1	- 7.8
Net non-operating assets *3	252.7	251.3	- 1.4
Total net assets	692.9	756.5	+ 63.6
Total assets	852.5	919.5	+ 67.0
Total liabilities	-159.6	-163.0	- 3.4

*1 Accrued receivable, accrued payable, accrued expenses, etc.

*2 Long-term prepaid expenses, long-term provisions, etc.

*3 Deferred tax assets, corporate income tax payable, etc.

Decrease in net working capital -15.6

- Decrease in inventories -9.7
  - Impact from front-loaded purchases in the previous year and transfer of long-term listed products, etc.
- Decrease in other net working capital -10.7

Increase in long-term net operating assets +80.6

- Increase in Property, plant and equipment +50.8
  - Purchase of a business site in Yokohama for a new laboratory
- Increase in Other long-term assets +28.2
  - Mainly decrease of the deferred income on applying IFRS15 and increase in long-term prepaid expenses for outsourcing of Manufacturing

Increase in net cash +6.4

Decrease in other non-operating assets - net -7.8

Equity ratio attributable to Chugai shareholders +1.0% pts.

- 2018 Dec 82.2%
- 2017 Dec 81.2%

FX rate to the JPY (end of period)

	2017 Dec	2018 Dec
1CHF	115.35	112.03
1EUR	134.82	126.13
1USD	112.89	110.28
1SGD	84.39	80.07

vs. 2017 Year End

Net Cash

(Billions of JPY)

Main investment for P.P.E

Ustunomiya: High-mix low-volume production capability for pre-filled syringe form products

Ukima: High-mix low-volume production of antibody API for initial commercial products

Fujieda: Solid formulation manufacturing facility, etc.

Main investment for P.P.E

Yokohama site: Purchase of business site

Ustunomiya: High-mix low-volume production capability for pre-filled syringe form products

Ukima Plant: High-mix low-volume production of antibody API for initial commercial products

Ukima Research Laboratories: Enhancement of the process development function of small- and middle-molecule active pharmaceutical ingredients



*1 Net effect of currency transactions on net cash, etc. = Transaction in own equity instruments + Net effect of currency translation on net cash(*2)

*2 A result of using different exchange rate types when consolidating overseas subsidiaries in financial statements, i.e. net cash using end of period exchange rate and free cash flow using average exchange rate. (Chugai defines this term based on International Accounting Standard (IAS) 7 and IAS 21)

Summary of Earnings Prospects for 2019

■ **Revenues: 592.5 billion yen (+12.7 +2.2% YoY)**

- Domestic sales [1]: decrease due to competition with generic drugs and impact of HIP revision (-10.8, -2.7%)
- Overseas sales: increase mainly due to Alecensa and Actemra export to Roche (+11.0, +8.6%)
- Royalty and profit-sharing income. [2]: increase in royalties from Roche for Hemlibra (+29.4, +122.0%)
- Other operating income [2]: decrease in one-time income from transfer of long-term listed products in the previous year, etc. (-16.9, -60.6%)

■ **Cost of sales / Operating expenses (Core basis)**

- Cost of sales: the ratio to sales will improve due to change in product mix, etc. (-1.8% points, from 49.6% to 47.8%)
- Operating expenses: overall increase mainly due to the increase of research and development expenses from progress of projects, etc. (-9.4, +5.0%)

■ **Profits (Core basis)**

Operating profit	143.0 billion yen	(+12.7, +9.7%)
EPS (JPY):	198.00	(+21.58, +12.2%)

1) Domestic sales include Tamiflu sales from FY2019.
2) Details of Royalty and profit-sharing income and Other operating income are shown separately from FY2019.

2019 Forecast (Core)

CHUGAI

Roche Roche Group

Forecast 2019 Jan - Dec

(Billions of JPY)	Actual 2018 Jan - Dec	vs. Revenues	Forecast 2019 Jan - Dec	vs. Revenues	Growth	
Revenues	**579.8**		**592.5**		**+12.7**	**+2.2%**
Sales	527.8		528.0		+0.2	+0.0%
Domestic	399.9		389.1		-10.8	-2.7%
Overseas	127.9		138.9		+11.0	+8.6%
Royalties and other operating income	51.9		64.5		+12.6	+24.3%
Royalty and profit-sharing income	24.1		53.5		+29.4	+122.0%
Other operating income	27.9		11.0		-16.9	-60.6%
Cost of Sales	-261.9		-252.5		+9.4	-3.6%
Gross Profit	**317.9**	**54.8%**	**340.0**	**57.4%**	**+22.1**	**+7.0%**
Operating Expenses	-187.6	32.4%	-197.0	33.2%	-9.4	+5.0%
Research and development expenses	-94.2		-102.0		-7.8	+8.3%
Operating Profit	**130.3**	**22.5%**	**143.0**	**24.1%**	**+12.7**	**+9.7%**
EPS (JPY)	176.42		198.00		+21.58	+12.2%

Increase in gross profit from sales +9.5

Despite decrease in domestic sales, increase in export to Roche

Increase in royalties and other operating income +12.6

Increase in royalties from Hemlibra, etc.

Increase in operating expenses -9.4

Increase in research and development -7.8

Progress of projects, etc.

Increase in research and development activities

Cost of sales ratio vs. Sales

2018 Jan – Dec	2019 Jan – Dec
49.6%	47.8%

Exchange rate (JPY)

	2018 Jan – Dec Actual *	2019 Jan – Dec Assumption
1CHF	112.92	114.00
1EUR	130.36	128.00
1USD	110.45	111.00
1SGD	81.87	82.00

*Actual: market average exchange rate for the period of Jan – Dec.

Movement of Operating Profit 2017 - 2019

(Billions of JPY)



Sales Forecast vs. 2018 Actual

(Billions of JPY)

Sales by Disease Area, Year on Year Comparisons



Sales by Products, Year on Year Changes



Details of HER2 franchise (54.3) +1.5 +2.8%

Herceptin: see the above		
Perjeta: see the above		
Kadcyla (9.1)	+0.6	+7.1%

( ): FY2019 forecast
%: Year-on-year percentage change

1) Tamiflu is included in “Others” from FY2019.

Outline of Hemlibra Sales to Roche



Current Status / Plan for Major Capital Investments

Main Objective

- Building of state-of-the-art R&D site to create innovative new drug candidates
- Simultaneous development and quick launch of therapeutic antibodies, etc.
- Reduction of manufacturing costs for in-house products
- Enhancement of the process development function of small- and middle- molecule active pharmaceutical ingredients

2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2026

C P R

CPR (Singapore): Accelerate creation of clinical candidates utilizing proprietary antibody technologies

2012-21: 476 million SGD (276 million SGD), incl. capital investments of 61 million SGD (59 million SGD)

2022-26: 282 million SGD, incl. capital investments of 21 million SGD

Domestic

Yokohama site: Purchase of business site

2016-18: 43.4 billion JPY (43.0 billion JPY)

Construction of laboratory

(Details to be officially announced upon final decision)

Utsunomiya Plant: Enhancement of high-mix low-volume production capability for pre-filled syringe form products (Installment of tray filler)

2013-18: 6.0 billion JPY (6.0 billion JPY)

Ukima Plant: Enhancement of high-mix low-volume production of antibody API for initial commercial products (Expansion of production capability by construction of UK3)

2015-18: 37.2 billion JPY (36.7 billion JPY)

Ukima Research Laboratories: Construction of a new synthetic research building for strengthening the process development function of small- and middle-molecule active pharmaceutical ingredients

2018-20: 4.5 billion JPY (1.3 billion JPY)

( ): Cumulative amount at the end of Dec., 2018

Dividend Policy

Policy

Aiming for a consolidated dividend payout ratio of 50% on average in comparison with Core EPS to provide a stable allocation of profit to all shareholders, taking into account the strategic funding needs and earnings prospects.

	Annual dividends per share (JPY)				Core payout ratio	
	Interim	End of FY	Special	Total	Single FY	5-year average
Dividends for FY2017 (Actual)	29	33	-	62	44.7%	48.4%
Dividends for FY2018 (Plan)	31	41	14	86	48.7%	48.6%
Dividends for FY2019 (Forecast)	48	48	-	96	48.5%	48.4%



Overview of Development Pipeline

CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President
Co-Head of Project & Lifecycle Management Unit
Dr. Yasushi Ito

January 31/ February 1, 2019

New Mid-Term Business Plan: 5 Strategies

CHUGAI
Roche Group

Accelerate corporate and social development through innovation focused on innovative products

Create global growth drivers and maximize value

1 Value Creation

Realize innovative drug discovery
to cure and manage diseases

2 Value Delivery

Deliver patient-centric solution
to maximize value of growth drivers

3 Promote advances in personalized healthcare

Realize the further advancement of PHC and innovate R&D process
by utilizing digital technology and data

Strengthen HR and infrastructure that support Chugai's business

4 Human capital and structural reform

Develop high-caliber HR talent that support innovation,
and drastically reform costs, systems and processes

5 Strengthen sustainable platforms

Simultaneously realize company growth and sustainable social development

Target during IBI 21

Create global growth drivers and maximize Value

No. of late stage development pipeline*	28 (including additional indication)

*Projects under development / launched products which already demonstrated PoC

Aiming to bring middle molecule projects into the clinical phase, and continuously develop innovative novel antibody engineering technologies

Value brought to Roche/Chugai by PHC 2.0

CHUGAI

Roche Roche Group

Smarter more efficient R&D

0101
1000
0101
1101
1011

Deep Scientific Insight

Better, earlier Go / No go decision

Faster won by efficient trials

Improve access & PHC

Better patient Tx matching

Enhanced physician Tx decision

RWD to improve access based on Value

Clinical Data

Genome information

Clinical genome information DB which satisfy the requirements of regulatory filing

Source: Roche slides

Design of FoundationOne CDx Report



FOUNDATIONONE CDx™

PATIENT Jane Sample | TUMOR TYPE Lung adenocarcinoma | TRF# TRFXXXXXX

PATIENT
DISEASE Lung adenocarcinoma
NAME Not Given
DATE OF BIRTH Not Given
SEX Female
MEDICAL RECORD # Not Given

PHYSICIAN
ORDERING PHYSICIAN Not Given
MEDICAL FACILITY Not Given
ADDITIONAL RECIPIENT Not Given
MEDICAL FACILITY ID Not Given
PATHOLOGIST Not Given

SPECIMEN
SPECIMEN SITE Not Given
SPECIMEN ID Not Given
SPECIMEN TYPE Not Given
DATE OF COLLECTION Not Given
SPECIMEN RECEIVED Not Given

CDx Associated Findings

GENOMIC FINDINGS DETECTED	FDA-APPROVED THERAPEUTIC OPTIONS
EGFR L858R	Gilotrif® (Afatinib) Iressa® (Gefitinib) Tarceva® (Erlotinib)

OTHER ALTERATIONS & BIOMARKERS IDENTIFIED
Results reported in this section are not prescriptive or conclusive for labeled use of any specific therapeutic product. See professional services section for additional information.

Microsatellite Status MS-Stable§
Tumor Mutation Burden 11 Muts/Mb§
CDKN2A/B loss§
EGFR amplification§
PTCH1 T416S
RBM10 Q494*
TP53 R267P

§Refer to appendix for limitation statements related to detection of any copy number alterations, gene rearrangements, MSI or TMB result in this section.
Please refer to appendix for Explanation of Clinical Significance Classification and for variants of unknown significance (VUS).

UMOR TYPE ung adenocarcinoma | TRF# TRFXXXXXX

ble
ntermediate (11 Muts/Mb)

se refer to the appendix.

no reportable alterations : *KRAS, ALK,*

patient's tumor type | 18 Clinical Trials

SPECIMEN SITE Not Given
SPECIMEN ID Not Given
SPECIMEN TYPE Not Given
DATE OF COLLECTION Not Given
SPECIMEN RECEIVED Not Given

7 Therapies with Clinical Benefit in other tumor type

BIOMARKER FINDINGS	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
Tumor Mutation Burden - TMB-Intermediate (11 Muts/Mb)	Atezolizumab	Avelumab
	Nivolumab	Durvalumab
9 Trials see p.14	Pembrolizumab	
Microsatellite status - MS-Stable	No therapies or clinical trials. see Biomarker Findings section	

GENOMIC FINDINGS	THERAPIES WITH CLINICAL BENEFIT (IN PATIENT'S TUMOR TYPE)	THERAPIES WITH CLINICAL BENEFIT (IN OTHER TUMOR TYPE)
EGFR - amplification, L858R	Afatinib	Cetuximab
	Erlotinib	Lapatinib
	Gefitinib	Panitumumab
4 Trials see p.15	Osimertinib	
PTCH1 - T416S	none	Sonidegib

Background information of Patient, Physician etc.

Summary of detected mutations

・Approval status of corresponding targeted therapies
・Ongoing clinical trials of detected mutations

Summary of references on detected mutations and candidates of therapy

Source : https://assets.ctfassets.net/vhribv12lmne/P1UbtVjOoeAcaOCWoWQkW/613003bbb4a62d6f06ab10b6e8367f92/FoundationOne_CDx_Sample_Report.pdf as of January 28, 2019

Overview of Development Pipeline

Projects under Development (1) (as of January 31, 2019)

	Phase I	Phase II	Phase III		Filed
Oncology	**CKI27** - solid tumors **GC33 (RG7686) / codrituzumab** - HCC★ **ERY974** - solid tumors **RG7421 / cobimetinib** - solid tumors **RG7802 / cibisatamab** - solid tumors **RG7828 / mosunetuzumab** - hematologic tumors	**RG6268 / entrectinib** - NSCLC	**RG3502 / Kadcyla** - breast cancer (adjuvant) **RG435 / Avastin** - RCC - HCC **RG7440 / ipatasertib** - prostate cancer - breast cancer **RG7596 / polatuzumab vedotin** - DLBCL **RG6264** - breast cancer (Fixed-dose combination, subcutaneous injection)	**AF802 (RG7853) / Alecensa** - NSCLC (adjuvant) **RG7446 / Tecentriq** - NSCLC (adjuvant) - urothelial carcinoma - MIUC (adjuvant) - RCC - RCC (adjuvant) - early breast cancer - ovarian cancer - prostate cancer - HCC - HNC (adjuvant)	**RG7446 / Tecentriq** - breast cancer ★ - SCLC ★ **RG6268 / entrectinib** - solid tumors ★
Bone & Joint			**NRD101 / Suvenyl (China)** - knee osteoarthritis /shoulder periarthritis		**ED-71 / Edirol (China)** - osteoporosis
Renal	**EOS789** - hyperphosphatemia				

In principle, completion of first dose is regarded as the start of clinical studies in each phase.

HCC: hepatocellular carcinoma
NSCLC: non-small cell lung cancer
SCLC: small cell lung cancer
MIUC: muscle invasive urothelial carcinoma
RCC: renal cell carcinoma
DLBCL: diffuse large B-cell lymphoma
HNC: head and neck carcinoma

Letters in orange: in-house projects
★: Projects with advances in stages since October 24, 2018
★: Multinational study managed by Chugai

Projects under Development (2) (as of January 31, 2019)

	Phase I	Phase II	Phase III	Filed
Autoimmune	**RG7845 / fenebrutinib** - rheumatoid arthritis		**MRA (RG1569) / Actemra** - systemic sclerosis	
Neurology	**RG7935 / prasinezumab** - Parkinson's disease **GYM329 (RG6237)** - neuromuscular disease **RG7906** - psychiatric disorders★	**RG7916 / risdiplam** - spinal muscular atrophy	**RG1450 / gantenerumab** - Alzheimer's disease **RG7412 / crenezumab** - Alzheimer's disease **SA237 (RG6168) / satralizumab** - NMOSD ★ **RG6206** - DMD (PII/III)	
Others	**PCO371** - hypoparathyroidism **RG7716 / faricimab** - wAMD **AMY109** - endometriosis	**CIM331 / nemolizumab*** - pruritus in dialysis patients **SKY59 (RG6107)** - paroxysmal nocturnal hemoglobinuria (PI/II)	**RG7716 / faricimab** - DME	**ACE910 (RG6013) / Hemlibra (EU)** - hemophilia A (non-inhibitor)

In principle, completion of first dose is regarded as the start of clinical studies in each phase.
wAMD: wet age-related macular degeneration
DME: diabetic macular edema
DMD: Duchenne muscular dystrophy
NMOSD: neuromyelitis optica spectrum disorder

* Atopic dermatitis is under development by licensees [Galderma (overseas) and Maruho (Japan)]

Letters in orange: in-house projects
★: Projects with advances in stages since October 24, 2018
★: Multinational study managed by Chugai

Development Status (1)

In-house

ACE910 / Hemlibra®

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A without factor VIII inhibitors, administered once weekly, every two weeks, or every four weeks. *

Approved in December 2018 (Japan)

Filed in January 2019 (Taiwan)

Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A with factor VIII inhibitors, administered once weekly.

Approved in December 2018 (Taiwan)

* Additional dosing options of every two weeks or every four weeks in adults and children with hemophilia A with factor VIII inhibitors are also included.

Development Status (2)

In-licensed

RG7446 / Tecentriq®

- Previously untreated unresectable advanced or recurrent non-squamous NSCLC (combination with Avastin and chemotherapy)
  - Approved in December 2018
- SCLC (1L)
  - Filed and designated as an Orphan drug in December 2018
- Triple negative breast cancer (1L)
  - Filed in December 2018
- HER2 positive early breast cancer (neoadjuvant) (combination with Herceptin and Perjeta)
  - Started global Phase 3 study (IMpassion050) in January 2019

In-licensed

RG6268 / entrectiniab

NTRK fusion positive solid tumors

Filed and designated as an Orphan drug in December 2018

In-licensed

RG7906

Psychiatric disorders

Started Phase 1 study in January 2019

Other Progress

FMI business

FoundationOne® CDx / Cancer Genomic profile

- Gene mutation analysis program for solid tumors (for use in cancer genome profiling)
  Somatic gene mutation analysis program (for use in assessing anticancer drug indications)
  - Approved in December 2018
- Expanded use as companion diagnostic for entrectinib
  - Filed in January 2019

In-house

SA237 / satralizumab

NMO / NMOSD

Breakthrough Therapy Designation by the U.S. FDA in December 2018

Results of Clinical Trials / Conference (1)

In-house

SKY59 (RG6107)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interim analysis data of Phase 1/2 study in patient subjects presented at the American Society of Hematology (ASH) in December 2018

- Complete complement inhibition was achieved for all PNH patients treated with SKY59 and good control of intravascular hemolysis was shown
- SKY59 was well tolerated and no severe adverse events were observed

Mean Terminal Complement Activity (LIA assay)



Mean Terminal Complement Activity (LIA assay)



Mean LDH Levels



Mean LDH Levels



Blue : Treatment naïve PNH patients
Brown : ECU pre-treated PNH patients switched to SKY59

LIA : Liposome Immuno Assay
LDH: lactate dehydrogenase
ECU: Eculizumab

Source : ASH (2018) slides

Results of Clinical Trials / Conference (2)

In-house

SA237 / satralizumab

NMOSD

Primary end point was met in SAkuraStar study (Phase 3) in December 2018

- Satralizumab routine administration statistically reduced the risk of relapse as primary endpoint compared to placebo

In-house

CIM331 / nemolizumab

Atopic dermatitis

Primary end point was met in Phase 2b study conducted by Galderma in October 2018

- Nemolizumab improved Eczema Area and Severity Index (EASI) scores from baseline compared to placebo

Projected Submissions (Post PoC NMEs and Products)

as of January 31, 2019

CHUGAI
Roche Roche Group

NME **line extension**

in-house
in-licensed

NSCLC: non-small cell lung cancer
RCC: renal cell carcinoma
SCLC: small cell lung cancer
MIUC: muscle invasive urothelial carcinoma
HCC: hepatocellular carcinoma
HNC: head and neck carcinoma
DLBCL: diffuse large B-cell lymphoma
NMOSD: neuromyelitis optica spectrum disorder
FDC: fixed-dose combination
sc: subcutaneous injection

Filed

2019	2020	2021 and beyond
TECENTRIQ (RG7446) SCLC	EDIROL (ED-71) Osteoporosis (China)	
TECENTRIQ (RG7446) Breast Cancer	HEMLIBRA (ACE910/RG6013) Hemophilia A non-inhibitor (EU)	
entrectinib (RG6268) Solid tumors (NTRK+)		
	TECENTRIQ (RG7446) Ovarian Cancer	ipatasertib (RG7440) Prostate Cancer
	AVASTIN (RG435) RCC	risdiplam (RG7916) Spinal Muscular Atrophy
	TECENTRIQ (RG7446) RCC	RG6206 Duchenne Muscular Dystrophy
ACTEMRA (MRA) Systemic Sclerosis	TECENTRIQ (RG7446) MIUC (adjuvant)	ipatasertib (RG7440) Breast Cancer
entrectinib (RG6268) NSCLC (ROS1+)	TECENTRIQ (RG7446) NSCLC (adjuvant)	KADCYLA (RG3502) Breast Cancer (adjuvant)
		TECENTRIQ (RG7446) HNC (adjuvant)
		AVASTIN (RG435) HCC
		TECENTRIQ (RG7446) HCC
		TECENTRIQ (RG7446) Prostate Cancer
		TECENTRIQ (RG7446) Early Breast Cancer
		TECENTRIQ (RG7446) RCC (adjuvant)
		TECENTRIQ (RG7446) Urothelial Carcinoma
satralizumab (SA237/RG6168) NMOSD		nemolizumab* (CIM331) Pruritus in Dialysis Patients
SUVENYL (NRD101) Knee Osteoarthritis /Shoulder Periarthritis (China)		faricimab (RG7716) Diabetic Macular Edema
		crenezumab (RG7412) Alzheimer's Disease
		gantenerumab (RG1450) Alzheimer's Disease
		ALECENSA (AF802/RG7853) NSCLC (adjuvant)
		RG6264 (FDC, sc) Breast cancer
		polatuzumab vedotin (RG7596) DLBCL

*Atopic dermatitis is under development by licensees [Galderma (overseas) and Maruho (Japan)]

Updates on the Development Requests for Unapproved Drugs/Indications

Review Committee of Development Requests for Unapproved Drugs/Indication

- 1st round requests: all approved (ten indications, including additional dosages and administrations of eight products)
- 2nd round requests: all approved (three indications of three products)
- 3rd round requests: requests were made for three indications of three products, including additional dosages and administrations, and two of them were approved

Product	Indication	Current Status
Avastin®	Additional dosage and administration for ovarian cancer	Submitted company opinion and waiting for evaluation by the committee

- 4th round requests: requests were made for four indications of four products and one of them was approved

Product	Indication	Current Status
Xeloda®	Neuroendocrine tumor	Submitted company opinion and waiting for evaluation by the committee
Avastin®	Cerebral edema induced by radiation necrosis	Submitted company opinion and waiting for evaluation by the committee
Neutrogin®	Combination treatment with chemotherapy including fludarabine for relapsed/refractory AML	Submitted company opinion and waiting for evaluation by the committee

Letters in orange: projects with advances in status since July 26, 2018

Contacts: Corporate Communications Dept.

Media Relations Group

Tel: +81 (0)3-3273-0881 Fax: +81 (0)3-3281-6607
e-mail: pr@chugai-pharm.co.jp

Tomoko Shimizu, Hiroshi Araki, Chisato Miyoshi, Yayoi Yamada,
Shumpei Yokoyama

Investor Relations Group

Tel: +81 (0)3-3273-0554 Fax: +81 (0)3-3281-6607
e-mail: ir@chugai-pharm.co.jp

Toshiya Sasai, Takayuki Sakurai, Tomoyuki Shimamura,
Sachiyo Yoshimura